BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 12865917)

  • 21. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast carcinoma in women 35 years and younger: a pathological study.
    Fernandopulle SM; Cher-Siangang P; Tan PH
    Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
    Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
    Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].
    Petráková K; Nenutil R; Grell P; Fabian P; Zichová I; Svoboda M; Palácová M; Vyzula R
    Klin Onkol; 2008; 21(5):303-8. PubMed ID: 19202962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; A'Hern R; Salter J; Detre S; Hills M; Walsh G;
    J Natl Cancer Inst; 2007 Jan; 99(2):167-70. PubMed ID: 17228000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
    Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
    Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
    Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular predictive factors for local recurrence and distant metastasis of breast cancer after lumpectomy with postoperative radiation therapy.
    Amornmarn R; Bui MM; Prempree TB; Masood S
    Ann Clin Lab Sci; 2000 Jan; 30(1):33-40. PubMed ID: 10678581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ.
    Yen TW; Hunt KK; Mirza NQ; Thomas ES; Singletary SE; Babiera GV; Meric-Bernstam F; Buchholz TA; Feig BW; Ross MI; Ames FC; Theriault RL; Kuerer HM
    Cancer; 2004 Mar; 100(5):942-9. PubMed ID: 14983489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
    Sullivan PS; Apple SK
    Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
    Sabine VS; Sims AH; Macaskill EJ; Renshaw L; Thomas JS; Dixon JM; Bartlett JM
    Breast Cancer Res Treat; 2010 Jul; 122(2):419-28. PubMed ID: 20480226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.
    Rao AV; Mohammed WA; Ragoonanan C; Omo-Igbinomwanhia NE
    West Indian Med J; 2002 Mar; 51(1):4-9. PubMed ID: 12089875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients.
    Richter-Ehrenstein C; Müller S; Noske A; Schneider A
    Int J Surg Pathol; 2009 Aug; 17(4):323-6. PubMed ID: 19029173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.